Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EBIT (2019 - 2025)

Historic EBIT for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$83.1 million.

  • Nurix Therapeutics' EBIT fell 2851.66% to -$83.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$285.7 million, marking a year-over-year decrease of 3409.85%. This contributed to the annual value of -$285.7 million for FY2025, which is 3409.85% down from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' EBIT is -$83.1 million, which was down 2851.66% from -$91.4 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' EBIT registered a high of -$24.5 million during Q1 2021, and its lowest value of -$91.4 million during Q3 2025.
  • For the 5-year period, Nurix Therapeutics' EBIT averaged around -$47.8 million, with its median value being -$45.5 million (2022).
  • In the last 5 years, Nurix Therapeutics' EBIT crashed by 9965.23% in 2021 and then soared by 4145.25% in 2023.
  • Nurix Therapeutics' EBIT (Quarter) stood at -$38.0 million in 2021, then fell by 28.29% to -$48.7 million in 2022, then grew by 6.89% to -$45.3 million in 2023, then crashed by 42.62% to -$64.7 million in 2024, then fell by 28.52% to -$83.1 million in 2025.
  • Its EBIT stands at -$83.1 million for Q4 2025, versus -$91.4 million for Q3 2025 and -$48.3 million for Q2 2025.